Treating the obese diabetic

Expert Review of Clinical Pharmacology

Volumn 6, Issue 2, 2013, Pages 171-183

  Kenkre, Julia ^a   Tan, Tricia ^a   Bloom, Stephen ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

bariatric surgery; DPP IV inhibitors; GLP 1 analogues; lorcaserin; obesity; orlistat; phentermine topiramate; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; AMFEBUTAMONE PLUS NALTREXONE; BROMOCRIPTINE; COLESEVELAM; DAPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; LORCASERIN; METFORMIN; PEPTIDE YY; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; QYSMIA; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; BARIATRIC SURGERY; BLADDER CANCER; BLOATING; BODY MASS; CALORIC RESTRICTION; CEREBROVASCULAR ACCIDENT; CONSTIPATION; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY SKIN; DYSPEPSIA; ECZEMA; EDEMA; FATIGUE; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; LACTIC ACIDOSIS; LEG SWELLING; LIFESTYLE MODIFICATION; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOLYSIS; PANCREATITIS; PATIENT EDUCATION; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; SATIETY; SIDE EFFECT; SLEEVE GASTRECTOMY; STOMACH MOTILITY; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; OBESITY; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84874905694     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.13.5     Document Type: Review

References (122)

1. Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29, 457-496 (1973
2. de Jager J, Kooy A, Lehert P et al. Long term treatment with metformin in patients with Type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ 340, c2181 (2010
3. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1), 33-37 (1999
4. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A metaanalysis of observational studies. Diabetes Care 31(8), 1672-1678 (2008
5. Bolen S, Feldman L, Vassy J et al. Systematic review: Comparative effectiveness and safety of oral medications for Type diabetes mellitus. Ann. Intern. Med. 147(6), 386-399 (2007
6. Krentz AJ. Management of Type 2 diabetes in the obese patient: Current concerns and emerging therapies. Curr. Med. Res. Opin. 24(2), 401-417 (2008
7. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in Type 2 diabetes. JAMA 303(14), 1410-1418 (2010
8. Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in Type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193-203 (2009
9. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with Type 2 diabetes mellitus and in obese patients without diabetes: A systematic review and meta-analysis. Diabetes. Obes. Metab. 13(2), 169-180 (2011
10. Younk LM, Davis SN. Evaluation of colesevelam hydrochloride for the treatment of Type 2 diabetes. Expert Opin. Drug Metab. Toxicol. 8(4), 515-525 (2012
11. Defronzo RA. Bromocriptine: A sympatholytic, d2-dopamine agonist for the treatment of Type 2 diabetes. Diabetes Care (4), 789-794 (2011
12. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in Type diabetes: Systematic review and meta-analysis. Diabetes. Obes. Metab. 13(11), 1008-1019 (2011 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352(9131), 837-853 (1998
13. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagonlike peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012
14. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of Type 2 diabetes mellitus in the clinical setting: Systematic review and metaanalysis. BMJ 344, e1369 (2012
15. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab. Vasc. Dis. Res. 9(2), 117-123 (2012
16. Whaley JM, Tirmenstein M, Reilly TP et al. Targeting the kidney and glucose excretion with dapagliflozin: Preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of Type 2 diabetes mellitus. Diabetes. Metab. Syndr. Obes. 5, 135-148 (2012
17. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat. Rev. Drug Discov. 10(9), 645-646 (2011
18. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin. Sci. 122(6), 253-270 (2012
19. Kirpichnikov D, McFarlane SI, Sowers Jr. Metformin: An update. Ann. Intern. Med. 137(1), 25-33 (2002
20. Boussageon R, Supper I, Bejan-Angoulvant T et al. Reappraisal of metformin efficacy in the treatment of Type 2 diabetes: A metaanalysis of randomised controlled trials. PLoS Med. 9(4), e1001204 (2012
21. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes. Obes. Metab. 13(3), 221-228 (2011
22. Golay A. Metformin and body weight. Int. J. Obes. (Lond.) 32(1), 61-72 (2008
23. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. 3, CD002966 (2005
24. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35(4), 731-737 (2012
25. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302(5910), 716-718 (1983
26. Holst JJ. Enteroglucagon. Annu. Rev. Physiol. 59, 257-271 (1997
27. Creutzfeldt W. The incretin concept today. Diabetologia 16(2), 75-85 (1979
28. Perfetti R, Merkel P. Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function. Eur. J. Endocrinol. 143(6), 717-725 (2000
29. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101(3), 515-520 (1998
30. Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a -week period in patients with early Type 2 diabetes. Clin. Sci. 95(3), 325-329 (1998
31. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214(3), 829-835 (1993
32. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: Systematic review and metaanalysis. JAMA 298(2), 194-206 (2007
33. Meier JJ. GLP-1 receptor agonists for individualized treatment of Type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8(12), 728-742 (2012
34. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560), 69-72 (1996
35. Näslund E, Bogefors J, Skogar S et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am. J. Physiol. 277(3 Pt 2), R910-R916 (1999
36. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in β-cell health. Diabetes Care 34(9), 2133-2135 (2011
37. Thong KY, Jose B, Sukumar N et al.; ABCD Nationwide Exenatide Audit Contributors. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes. Obes. Metab. 13(8), 703-710 (2011
38. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: A systematic review of the literature. Diabetes. Obes. Metab. doi:10.1111/dom.12025 (2012) (Epub ahead of print
39. Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin: Therapeutic rationales and clinical findings. Diabetes. Obes. Metab. 15(1), 3-14 (2013
40. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of Type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 30(6), 1335-1343 (2007
41. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2, CD006739 (2008
42. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of Type 2 diabetes. Diabetes. Metab. Syndr. Obes. 5, 313-327 (2012
43. Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: A new emerging therapeutic class in the treatment of Type 2 diabetes mellitus. J. Clin. Pharmacol. 52(4), 457-463 (2012
44. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with Type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 375(9733), 2223-2233 (2010
45. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL et al. Reduction in weight and cardiovascular disease risk factors in individuals with Type 2 diabetes: One-year results of the look AHEAD trial. Diabetes Care 30(6), 1374-1383 (2007
46. diabetes is effective at producing both significant weight loss and significant improvement in glycemia. 47 Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: A systematic review of studies published between 1931 and 1999. Obes. Rev. 1(2), 113-119 (2000
47. Norris SL, Zhang X, Avenell A et al. Long-term non-pharmacological weight loss interventions for adults with Type 2 diabetes (Review). Cochrane Database Syst. Rev. 2, CD004095 (2005
48. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of Type 2 diabetes: Normalisation of β cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54(10), 2506-2514 (2011
49. Picot J, Jones J, Colquitt JL et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: A systematic review and economic evaluation. Health Technol. Assess. 13(41), 1-190, 215 (2009
50. Carlsson LM, Peltonen M, Ahlin S et al. Bariatric surgery and prevention of Type 2 diabetes in Swedish obese subjects. N. Engl. J. Med. 367(8), 695-704 (2012
51. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222(3), 339-350; discussion (1995
52. Sjöström L. Bariatric surgery and reduction in morbidity and mortality: Experiences from the SOS study. Int. J. Obes. (Lond (Suppl. 7), S93-S97 (2008
53. Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357(8), 753-761 (2007
54. Romeo S, Maglio C, Burza MA et al. Cardiovascular events after bariatric surgery in obese subjects with Type 2 diabetes. Diabetes Care 35(12), 2613-2617 (2012
55. Trus TL, Pope GD, Finlayson SR. National trends in utilization and outcomes of bariatric surgery. Surg. Endosc. 19(5), 616-620 (2005
56. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes. Surg. 19(12), 1605-1611 (2009
57. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2011. Diabetes Care 34(Suppl. 1), S4-10 (2011
58. Dixon JB, Zimmet P, Alberti KG, Rubino F; International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: An IDF statement for obese Type 2 diabetes. Diabet. Med. 28(6), 628-642 (2011
59. Lanzarini E, Csendes A, Gutierrez L et al. Type 2 diabetes mellitus in patients with mild obesity: Preliminary results of surgical treatment. Obes. Surg. doi:10.1007/s11695-012-0780-3 (2012) (Epub ahead of print
60. Buchwald H, Estok R, Fahrbach K et al. Weight and Type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am. J. Med. 122(3), 248-256.e5
61. Pournaras DJ, Aasheim ET, Søvik TT et al. Effect of the definition of Type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br. J. Surg. 99(1), 100-103 (2012
62. Schauer PR, Kashyap SR, Wolski K et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366(17), 1567-1576 (2012
63. Mingrone G, Panunzi S, De Gaetano A et al. Bariatric surgery versus conventional medical therapy for Type 2 diabetes. N. Engl. J. Med. 366(17), 1577-1585 (2012
64. Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for Type 2 diabetes. Lancet 379(9833), 2300-2311 (2012
65. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: A time course study. Obes. Surg. 15(4), 474-481 (2005
66. Laurenius A, Larsson I, Bueter M et al. Changes in eating behaviour and meal pattern following Roux-en-Y gastric bypass. Int. J. Obes. (Lond.) 36(3), 348-355 (2012
67. le Roux CW, Aylwin SJ, Batterham RL et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 243(1), 108-114 (2006
68. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349(10), 941-948 (2003
69. Neary NM, Small CJ, Druce MR et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146(12), 5120-5127 (2005
70. van den Hoek AM, Heijboer AC, Corssmit EPM et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53(8), 1949-1952 (2004
71. Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial. Int. J. Obes. (Lond.) 30(12), 1729-1736 (2006
72. Wynne K, Park AJ, Small CJ et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: A double-blind, randomized, controlled trial. Diabetes 54(8), 2390-2395 (2005
73. Laferrère B, Swerdlow N, Bawa B et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 95(8), 4072-4076 (2010
74. Parlevliet ET, Heijboer AC, Schröder-van der Elst JP et al. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 294(1), E142-E147 (2008
75. Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: A review. J. Am. Diet. Assoc. 110(4), 571-584 (2010
76. Rubino F, Gagner M, Gentileschi P et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann. Surg. 240(2), 236-242 (2004
77. Chia CW, Carlson OD, Kim W et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in Type 2 diabetes. Diabetes 58(6), 1342-1349 (2009
78. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 66(2), 91-103 (2000
79. Pournaras DJ, Glicksman C, Vincent RP et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology (8), 3613-3619 (2012
80. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122), 1027-1031 (2006
81. Holmes E, Kinross J, Gibson GR et al. Therapeutic modulation of microbiota-.host metabolic interactions. Sci. Transl. Med. 4(137), 137rv6 (2012
82. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: Updated metaanalysis. BMJ 335(7631), 1194-1199 (2007
83. Li Z, Maglione M, Tu W et al. Meta-analysis: Pharmacologic treatment of obesity. Ann. Intern. Med. 142(7), 532-546 (2005
84. Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with Type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21(8), 1288-1294 (1998
85. Miles JM, Leiter L, Hollander P et al. Effect of orlistat in overweight and obese patients with Type 2 diabetes treated with metformin. Diabetes Care 25(7), 1123-.1128 (2002
86. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 27(1), 155-161 (2004
87. Derosa G, Maffioli P. Anti-obesity drugs: A review about their effects and their safety. Expert Opin. Drug Saf. 11(3), 459-471 (2012
88. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol. Psychiatry (9), 851-864 (1998
89. Lam DD, Przydzial MJ, Ridley SH et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149(3), 1323-1328 (2008
90. O'Neil PM, Smith SR, Weissman NJ et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in Type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring) 20(7), 1426-1436 (2012
91. Astrup A. Drug management of obesity - efficacy versus safety. N. Engl. J. Med. 363(3), 288-290 (2010
92. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N. Engl. J. Med. 367(17), 1577-1579 (2012
93. Thomsen WJ, Grottick AJ, Menzaghi F et al. Lorcaserin, a novel selective human-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325(2), 577-587 (2008
94. Colman E. Anorectics on trial: A half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. 143(5), 380-385 (2005
95. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26(2), 262-273 (2002
96. Kang JG, Park CY. Anti-obesity drugs: A review about their effects and safety. Diabetes Metab. J. 36(1), 13-25 (2012
97. Astrup A, Caterson I, Zelissen P et al. Topiramate: Long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 12(10), 1658-1669 (2004
98. Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11(6), 722-733 (2003
99. Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341-1352 (2011
100. Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, Phase 3 extension study. Am. J. Clin. Nutr. 95(2), 297-308 (2012
101. Hollander P, Plodkowski R, Gupta AK et al. COR-Diabetes: Naltrexone SR/bupropion SR combination therapy led to significant and sustained weight loss and improved HbA1c in overweight/obese subjects with Type 2 diabetes. Diabetes (Suppl. 1), Abstract 56-OR (2010
102. Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Ann. Med. 43(4), 249-258 (2011
103. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418(6898), 650-654 (2002
104. Gantz I, Erondu N, Mallick M et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab. 92(5), 1754-1757 (2007
105. Batterham RL, Le Roux CW, Cohen MA et al. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. 88(8), 3989-3992 (2003
106. Jesudason DR, Monteiro MP, McGowan BM et al. Low-dose pancreatic polypeptide inhibits food intake in man. Br. J. Nutr. 97(3), 426-429 (2007
107. Tan TM, Field BC, Minnion JS et al. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br. J. Clin. Pharmacol. 73(2), 232-239 (2012
108. Field BC, Wren AM, Peters V et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes (7), 1635-1639 (2010
109. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int. J. Obes. Relat. Metab. Disord. 24(3), 288-298 (2000
110. Geary N. Pancreatic glucagon signals postprandial satiety. Neurosci. Biobehav. Rev. 14(3), 323-338 (1990
111. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J. Clin. Endocrinol. Metab. 64(5), 896-901 (1987
112. Pocai A, Carrington PE, Adams JR et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58(10), 2258-2266 (2009
113. Tan TM, Field BC, McCullough KA et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in man results in increased energy expenditure and amelioration of hyperglycemia. Diabetes doi:10.2337/db12-0797 (2012) (Epub ahead of print
114. Gerrald KR, Van Scoyoc E, Wines RC, Runge T, Jonas DE. Saxagliptin and sitagliptin in adult patients with Type 2 diabetes: A systematic review and metaanalysis. Diabetes. Obes. Metab. 14(6), 481-492 (2012
115. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with Type 2 diabetes. Pharmacology 86(1), 44-57 (2010
116. Neumiller JJ, Setter SM. Review of linagliptin for the treatment of Type 2 diabetes mellitus. Clin. Ther. 34(5), 993-1005 (2012
117. Esposito K, Cozzolino D, Bellastella G et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in Type 2 diabetes: Meta-analysis of randomized controlled trials. Diabetes. Obes. Metab. 13(7), 594-603 (2011
118. Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of Type 2 diabetes. Expert Opin. Pharmacother. 13(4), 553-563 (2012
119. Spanakis E, Gragnoli C. Bariatric surgery, safety and Type 2 diabetes. Obes. Surg. 19(3), 363-368 (2009
120. Buchwald H. A bariatric surgery algorithm. Obes. Surg. 12(6), 733-46; discussion 747 (2002
121. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 292(14), 1724-1737 (2004
122. Hutter MM, Schirmer BD, Jones DB et al. First report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann. Surg. 254(3), 410-420; discussion 420 (2011